<DOC>
	<DOCNO>NCT01221545</DOCNO>
	<brief_summary>The purpose study investigate safety tolerability high Single Ascending Oral Doses AZD1656 .</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability , Pharmacokinetics , Pharmacodynamics After High Single Ascending Oral Doses AZD1656 T2DM Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Provision sign date , write informed consent prior study specific procedure . Male , T2DM patient age 2060 year Treatment 1 2 OADs Therapy T2DM least 30 day prior enrollment Patients treat glitazones within 6 month prior enrollment Male T2DM patient without know cardiovascular disease , exception Grade 1 hypertension without secondary organ involvement ( eg . grade 1 HT allow eye , kidney disease LVH document ) . History ischemic heart disease , heart failure , stroke , transitory ischemic attack peripheral vascular disease . Prolonged QTcF &gt; 450 msec shorten QTcF &lt; 350 msec family history long QT syndrome . Any clinically important abnormality rhythm , conduction morphology rest ECG may interfere interpretation QTc interval change . Systolic BP &gt; 159 mmHg diastolic BP &gt; 99 mmHg screening Day1</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Diabetes Mellitus</keyword>
</DOC>